Discounted Cash Flow
Alnylam Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $47.2m | $-410.1m | $-372.3m | -869.6% | $-4.79 |
| 2017 | $89.9m (90.7%) | $-490.9m (-19.7%) | $-487.0m (-30.8%) | -545.9% (37.2%) | $-5.42 (-13.2%) |
| 2018 | $74.9m (-16.7%) | $-761.5m (-55.1%) | $-689.5m (-41.6%) | -1016.6% (-86.2%) | $-7.57 (-39.7%) |
| 2019 | $219.8m (193.4%) | $-886.1m (-16.4%) | $-418.6m (39.3%) | -403.2% (60.3%) | $-8.11 (-7.1%) |
| 2020 | $492.9m (124.3%) | $-858.3m (3.1%) | $-685.3m (-63.7%) | -174.1% (56.8%) | $-7.46 (8.0%) |
| 2021 | $844.3m (71.3%) | $-852.8m (0.6%) | $-718.1m (-4.8%) | -101.0% (42.0%) | $-7.20 (3.5%) |
| 2022 | $1.0b (22.9%) | $-1.1b (-32.6%) | $-613.3m (14.6%) | -109.0% (-7.9%) | $-9.30 (-29.2%) |
| 2023 | $1.8b (76.2%) | $-440.2m (61.1%) | $41.9m (106.8%) | -24.1% (77.9%) | $-3.52 (62.2%) |
| 2024 | $2.2b (23.0%) | $-278.2m (36.8%) | $-42.6m (-201.5%) | -12.4% (48.6%) | $-2.18 (38.1%) |
| 2025 | $3.7b (65.2%) | $313.7m (212.8%) | $465.4m (1192.7%) | 8.4% (168.3%) | $2.39 (209.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.